Acrongenomics, Inc. Appoints Chief Technology Officer
February 24 , 2006
Geneva, Switzerland--Acrongenomics,Inc. (OTCBB:AGNM) announced today the appointment of Dr. Manos Topoglidis to its Board of Directors & Scientific Advisory Board as Chief Technology Officer.
In his new role, Dr. Topoglidis will be responsible for providing Acrongenomics' management team with a solid scientific and technical vision. This includes understanding and translating Acrongenomics' science and technology-based capabilities into competitive advantages, implementing a compelling R&D pipeline and collaborating with government, academia and industry leaders in the life sciences industry. Dr. Topoglidis will also play a significant role in leading the Company's research team to define and assess viable opportunities for Acrongenomics, with particular interest in the realm of biosensors.
Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications which have been cited worldwide.
"In this new, ever-changing field of nanobiotechnology, it is paramount for our team to stay on top of the pioneering technologies, trends and unmet needs in the medical community," states Constantine Poulios, President of Acrongenomics. "Dr. Topoglidis' unique and in-depth background in the fields of nanotechnology and biology made him the ideal candidate to direct our technological vision. He provides invaluable experience relating to the intricacies of our current nanotechnology projects and will also set the tone in determining Acrongenomics' future biotechnology solutions."
Acrongenomics also announces new headquarters in Geneva, Switzerland to accommodate its forthcoming expansion phase, grow its collaborative network and centrally position itself in a first-rate European market. In addition to its rank as the leading financial center of Europe, Switzerland is a global leader in scientific and life sciences research, making it an excellent location. With a bustling biotechnology sector, Switzerland exhibits a solid cluster of world-class Universities, pharmaceutical giants, burgeoning biotech companies, key government organizations and industry associations. Acrongenomics is thrilled to explore the opportunities offered by the dynamic European economy.
About Acrongenomics, Inc.
Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its international headquarters in Geneva, Switzerland.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
